Development, physical-chemical characterization and in vitro antibacterial activity evaluation of a fixed-dose combination isohydrafural-methyluracil hydrophilic ointment

Rus Lucia Maria; Donici Elena; Valica Vladimir; Prisakari Viorel I.; Tomuta Ioan; Shepel Diana; Heghes Simona Codruta; Iuga Cristina Adela; Uncu Livia

Conţinutul numărului revistei

Articolul precedent

Articolul urmator

1701

SM ISO690:2012

RUS, Lucia Maria, DONICI, Elena, VALICA, Vladimir, PRISAKARI, Viorel I., TOMUTA, Ioan, SHEPEL, Diana, HEGHES, Simona Codruta, IUGA, Cristina Adela, UNCU, Livia. Development, physical-chemical characterization and in vitro antibacterial activity evaluation of a fixed-dose combination isohydrafural-methyluracil hydrophilic ointment. In: Farmacia, 2019, nr. 5(67), pp. 857-865. ISSN 0014-8237. DOI: https://doi.org/ 10.31925/farmacia.2019.5.15

EXPORT metadate:
Google Scholar
Crossref
CERIF

DataCite
Dublin Core

Farmacia

Numărul 5(67) / 2019 / ISSN 0014-8237

Development, physical-chemical characterization and in vitro antibacterial activity evaluation of a fixed-dose combination isohydrafural-methyluracil hydrophilic ointment

DOI:https://doi.org/ 10.31925/farmacia.2019.5.15

Pag. 857-865

Rus Lucia Maria¹, Donici Elena², Valica Vladimir², Prisakari Viorel I.², Tomuta Ioan¹, Shepel Diana³, Heghes Simona Codruta¹, Iuga Cristina Adela¹, Uncu Livia²

¹ Iuliu Haţieganu University of Medicine and Pharmacy Cluj-Napoca,
² ”Nicolae Testemițanu” State University of Medicine and Pharmacy,
³ Institute of Chemistry

Disponibil în IBN: 26 octombrie 2019

Rezumat

This research was focused on the pharmaceutical development of a novel, fixed-dose combination isohydrafural-methyluracil ointment on a water soluble base-polyethylene glycol (PEG). Differential scanning calorimetry (DSC) and Fourier transform infra-red spectroscopy (FTIR) were applied in order to determine the compatibility between active pharmaceutical ingredients (APIs) and between APIs-excipients. Nine formulations (F1-F9) were tested for: physical appearance and homogeneity, pH, viscosity and osmotic activity. The optimal formulation presented the concentrations of PEG 400-76.72%, PEG 1500-19.18% and a fixed-dose combination of 0.1% isohydrafural and 4% methyluracil. It showed higher antibacterial properties both to Gram-positive and Gram-negative bacteria than nitrofural 2% ointment (Furacilin®, Belarus). The long-term stability testing of the optimized formulation of isohydrafural and methyluracil revealed the shelf-life of two years.

Cuvinte-cheie
In vitro antibacterial activity, Pharmaceutical preformulation, Stability evaluation

Cerif XML Export

<?xml version='1.0' encoding='utf-8'?>
<CERIF xmlns='urn:xmlns:org:eurocris:cerif-1.5-1' xsi:schemaLocation='urn:xmlns:org:eurocris:cerif-1.5-1 http://www.eurocris.org/Uploads/Web%20pages/CERIF-1.5/CERIF_1.5_1.xsd' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' release='1.5' date='2012-10-07' sourceDatabase='Output Profile'>
<cfResPubl>
<cfResPublId>ibn-ResPubl-86410</cfResPublId>
<cfResPublDate>2019-10-15</cfResPublDate>
<cfVol>67</cfVol>
<cfIssue>5</cfIssue>
<cfStartPage>857</cfStartPage>
<cfISSN>0014-8237</cfISSN>
<cfURI>https://ibn.idsi.md/ro/vizualizare_articol/86410</cfURI>
<cfTitle cfLangCode='EN' cfTrans='o'>Development, physical-chemical characterization and in vitro antibacterial activity evaluation of a fixed-dose combination isohydrafural-methyluracil hydrophilic ointment</cfTitle>
<cfKeyw cfLangCode='EN' cfTrans='o'>In vitro antibacterial activity; Pharmaceutical preformulation; Stability evaluation</cfKeyw>
<cfAbstr cfLangCode='EN' cfTrans='o'><p>This research was focused on the pharmaceutical development of a novel, fixed-dose combination isohydrafural-methyluracil ointment on a water soluble base-polyethylene glycol (PEG). Differential scanning calorimetry (DSC) and Fourier transform infra-red spectroscopy (FTIR) were applied in order to determine the compatibility between active pharmaceutical ingredients (APIs) and between APIs-excipients. Nine formulations (F1-F9) were tested for: physical appearance and homogeneity, pH, viscosity and osmotic activity. The optimal formulation presented the concentrations of PEG 400-76.72%, PEG 1500-19.18% and a fixed-dose combination of 0.1% isohydrafural and 4% methyluracil. It showed higher antibacterial properties both to Gram-positive and Gram-negative bacteria than nitrofural 2% ointment (Furacilin&reg;, Belarus). The long-term stability testing of the optimized formulation of isohydrafural and methyluracil revealed the shelf-life of two years.</p></cfAbstr>
<cfResPubl_Class>
<cfClassId>eda2d9e9-34c5-11e1-b86c-0800200c9a66</cfClassId>
<cfClassSchemeId>759af938-34ae-11e1-b86c-0800200c9a66</cfClassSchemeId>
<cfStartDate>2019-10-15T24:00:00</cfStartDate>
</cfResPubl_Class>
<cfResPubl_Class>
<cfClassId>e601872f-4b7e-4d88-929f-7df027b226c9</cfClassId>
<cfClassSchemeId>40e90e2f-446d-460a-98e5-5dce57550c48</cfClassSchemeId>
<cfStartDate>2019-10-15T24:00:00</cfStartDate>
</cfResPubl_Class>
<cfPers_ResPubl>
<cfPersId>ibn-person-67424</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2019-10-15T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-42764</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2019-10-15T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-11802</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2019-10-15T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-246</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2019-10-15T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-47334</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2019-10-15T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-12468</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2019-10-15T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-67426</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2019-10-15T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-67427</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2019-10-15T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-12094</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2019-10-15T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfFedId>
<cfFedIdId>ibn-doi-86410</cfFedIdId>
<cfFedId> 10.31925/farmacia.2019.5.15</cfFedId>
<cfStartDate>2019-10-15T24:00:00</cfStartDate>
<cfFedId_Class>
<cfClassId>31d222b4-11e0-434b-b5ae-088119c51189</cfClassId>
<cfClassSchemeId>bccb3266-689d-4740-a039-c96594b4d916</cfClassSchemeId>
</cfFedId_Class>
<cfFedId_Srv>
<cfSrvId>5123451</cfSrvId>
<cfClassId>eda2b2e2-34c5-11e1-b86c-0800200c9a66</cfClassId>
<cfClassSchemeId>5a270628-f593-4ff4-a44a-95660c76e182</cfClassSchemeId>
</cfFedId_Srv>
</cfFedId>
</cfResPubl>
<cfPers>
<cfPersId>ibn-Pers-67424</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-67424-3</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2019-10-15T24:00:00</cfStartDate>
<cfFamilyNames>Rus</cfFamilyNames>
<cfFirstNames>Lucia Maria</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-42764</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-42764-3</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2019-10-15T24:00:00</cfStartDate>
<cfFamilyNames>Donici</cfFamilyNames>
<cfFirstNames>Elena</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-11802</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-11802-3</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2019-10-15T24:00:00</cfStartDate>
<cfFamilyNames>Valica</cfFamilyNames>
<cfFirstNames>Vladimir</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-246</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-246-3</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2019-10-15T24:00:00</cfStartDate>
<cfFamilyNames>Prisakari</cfFamilyNames>
<cfFirstNames>Viorel I.</cfFirstNames>
<cfFamilyNames>Присакарь</cfFamilyNames>
<cfFirstNames>Виорел</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-47334</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-47334-3</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2019-10-15T24:00:00</cfStartDate>
<cfFamilyNames>Tomuta</cfFamilyNames>
<cfFirstNames>Ioan</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-12468</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-12468-3</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2019-10-15T24:00:00</cfStartDate>
<cfFamilyNames>Shepel</cfFamilyNames>
<cfFirstNames>Diana</cfFirstNames>
<cfFamilyNames>Шепель</cfFamilyNames>
<cfFirstNames>Диана</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-67426</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-67426-3</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2019-10-15T24:00:00</cfStartDate>
<cfFamilyNames>Heghes</cfFamilyNames>
<cfFirstNames>Simona Codruta</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-67427</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-67427-3</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2019-10-15T24:00:00</cfStartDate>
<cfFamilyNames>Iuga</cfFamilyNames>
<cfFirstNames>Cristina Adela</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-12094</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-12094-3</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2019-10-15T24:00:00</cfStartDate>
<cfFamilyNames>Uncu</cfFamilyNames>
<cfFirstNames>Livia</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfSrv>
<cfSrvId>5123451</cfSrvId>
<cfName cfLangCode='en' cfTrans='o'>CrossRef DOI prefix service</cfName>
<cfDescr cfLangCode='en' cfTrans='o'>The service of issuing DOI prefixes to publishers</cfDescr>
<cfKeyw cfLangCode='en' cfTrans='o'>persistent identifier; Digital Object Identifier</cfKeyw>
</cfSrv>
</CERIF>